Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada
暂无分享,去创建一个
Richard D Moore | J. Goedert | Haiqun Lin | T. Sterling | N. Hessol | R. Bosch | A. Justice | M. Horberg | E. Engels | C. Achenbach | R. U. Hernández-Ramírez | R. Neugebauer | M. Kitahata | M. Silverberg | W. Leyden | S. Grover | C. Rabkin | G. D’Souza | R. Dubrow | R. Novak | K. Althoff | A. Mayor | S. Modur | L. Qin | R. Hernández-Ramírez | Á. Mayor | Richard D. Moore
[1] A. Justice,et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997–2012 , 2016, AIDS.
[2] O. Kirk,et al. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? , 2016, AIDS.
[3] T. VanderWeele. Mediation Analysis: A Practitioner's Guide. , 2016, Annual review of public health.
[4] Richard D Moore,et al. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. , 2015, Annals of internal medicine.
[5] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[6] C. Sabin,et al. Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy: The D:A:D Study , 2015, Journal of acquired immune deficiency syndromes.
[7] R. Pfeiffer,et al. Excess cancers among HIV-infected people in the United States. , 2015, Journal of the National Cancer Institute.
[8] M. Bower,et al. Facing up to the ongoing challenge of Kaposi's sarcoma , 2015, Current opinion in infectious diseases.
[9] B. Chi,et al. Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa: A Prospective Multicohort Study , 2014, Journal of acquired immune deficiency syndromes.
[10] M. Egger,et al. Kaposi's Sarcoma in HIV‐infected patients in South Africa: Multicohort study in the antiretroviral therapy era , 2014, International journal of cancer.
[11] Y. Guo,et al. Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway , 2014, Oncogene.
[12] R. Pfeiffer,et al. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States , 2014, AIDS.
[13] A. Zolopa,et al. Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations. , 2014, Antiviral research.
[14] M. Silverberg,et al. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk , 2014, Current opinion in HIV and AIDS.
[15] D. Costagliola,et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] B. Gazzard,et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] T. Maurer,et al. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection , 2013, AIDS.
[18] C. Sabin,et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers , 2013, AIDS.
[19] Shou-Jiang Gao,et al. HIV-1 Tat Promotes Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) vIL-6-Induced Angiogenesis and Tumorigenesis by Regulating PI3K/PTEN/AKT/GSK-3β Signaling Pathway , 2013, PloS one.
[20] A. Justice,et al. HIV infection, aging, and immune function: implications for cancer risk and prevention , 2012, Current opinion in oncology.
[21] A. Semeere,et al. Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings , 2012, Current opinion in oncology.
[22] D. Klein,et al. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[23] D. Whitby,et al. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. , 2011, Cancer letters.
[24] K. H. Hullsiek,et al. Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? , 2010, AIDS.
[25] Ethel Cesarman,et al. Kaposi's sarcoma and its associated herpesvirus , 2010, Nature Reviews Cancer.
[26] E. Bonmassar,et al. Spindle cells from AIDS-associated Kaposi's sarcoma lesions express telomerase activity that is enhanced by Kaposi's sarcoma progression factors. , 2010, Oncology reports.
[27] S. Franceschi,et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study , 2010, British Journal of Cancer.
[28] M. Guiguet,et al. Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion , 2010, Journal of the National Cancer Institute.
[29] Richard D Moore,et al. Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy Era , 2009, Journal of acquired immune deficiency syndromes.
[30] M. Guiguet,et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.
[31] X. Fang,et al. Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. , 2009, Neoplasia.
[32] A. Sasco,et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] J. van Lunzen,et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. , 2009, The Journal of infectious diseases.
[34] S. Franceschi,et al. Cancer risk in HIV-infected persons: influence of CD4(+) count. , 2009, Future oncology.
[35] B. Gazzard,et al. CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK , 2009, Haematologica.
[36] S. Franceschi,et al. Kaposi sarcoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy , 2009, British Journal of Cancer.
[37] J. Goedert,et al. Cancer risk in people infected with human immunodeficiency virus in the United States , 2008, International journal of cancer.
[38] P. Sullivan,et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.
[39] Edu,et al. Journal of Experimental & Clinical Cancer Research Hiv-1 Tat and Aids-associated Cancer: Targeting the Cellular Anti-cancer Barrier? Aids and Cancer Two Other Types of Cancer Have Been Associated with Aids. Hiv-1 Infected Patients Develop Lymphomas at Relatively , 2008 .
[40] T. Powles,et al. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. , 2008, AIDS.
[41] N. Lane. More on HIV-Associated Kaposi's Sarcoma , 2008 .
[42] T. Maurer,et al. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. , 2007, The New England journal of medicine.
[43] B. Gazzard,et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count , 2007, AIDS.
[44] P. Harrigan,et al. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients , 2007, AIDS.
[45] J. Goedert,et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. , 2007, Journal of the National Cancer Institute.
[46] Richard D Moore,et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). , 2007, International journal of epidemiology.
[47] C. Barone,et al. Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors. , 2007, Current pharmaceutical design.
[48] Zan Huang,et al. Intracellular Tat of Human Immunodeficiency Virus Type 1 Activates Lytic Cycle Replication of Kaposi's Sarcoma-Associated Herpesvirus: Role of JAK/STAT Signaling , 2006, Journal of Virology.
[49] J. Goedert,et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma , 2006, Cancer.
[50] E. Arbustini,et al. Kaposi’s Sarcoma in Transplant and HIV-infected Patients: An Epidemiologic Study in Italy and France , 2005, Transplantation.
[51] S. Remick,et al. Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya , 2005, Annals of tropical medicine and parasitology.
[52] A. Mocroft,et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003 , 2004, Cancer.
[53] M. Rusnati,et al. HIV-1 Tat protein and endothelium: From protein/cell interaction to AIDS-associated pathologies , 2004, Angiogenesis.
[54] P. Monini,et al. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. , 2003, The Lancet. Oncology.
[55] J. Goedert,et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma , 2003, AIDS.
[56] David R. Anderson,et al. Model selection and multimodel inference : a practical information-theoretic approach , 2003 .
[57] G. Barillari,et al. Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma , 2002, Clinical Microbiology Reviews.
[58] D. Trichopoulos,et al. The role of immunosuppression and immune‐activation in classic Kaposi's sarcoma , 1999, International journal of cancer.
[59] J. Goedert,et al. Plasma HIV Viral Load in Patients with Hemophilia and Late-Stage HIV Disease: A Measure of Current Immune Suppression , 1999, Annals of Internal Medicine.